Summit Therapeutics Inc.
SMMT
Rang în acțiuni
#1707
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Preț acțiune
$15.71
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$12.53B
Schimbare (1 zi)
7.35%
Schimbare (1 an)
-21.63%
Țară
US
Tranzacționează Summit Therapeutics Inc. (SMMT)
Categorie
Healthcare
EPS pentru Summit Therapeutics Inc. (SMMT)
EPS la data de June 2026 TTM: $-1.12
Conform celor mai recente rapoarte financiare și prețului acțiunilor Summit Therapeutics Inc., EPS-ul actual al companiei (TTM) este $-1.12. La sfârșitul anului 2023, compania avea un EPS de $-0.99 o creștere față de EPS-ului din 2022, care a fost de $-0.41.
Istoricul EPS pentru Summit Therapeutics Inc. din 2004 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| 2026 (TTM) | $-1.12 | 261.29% |
| 2024 | $-0.31 | -68.69% |
| 2023 | $-0.99 | 141.46% |
| 2022 | $-0.41 | -57.29% |
| 2021 | $-0.96 | 26.32% |
| 2020 | $-0.76 | 282.10% |
| 2019 | $-0.20 | -12.46% |
| 2018 | $-0.23 | -58.03% |
| 2017 | $-0.54 | -7.28% |
| 2016 | $-0.58 | -9.84% |
| 2015 | $-0.65 | 15.87% |
| 2014 | $-0.56 | -16.06% |
| 2013 | $-0.67 | 17.30% |
| 2012 | $-0.57 | 86.96% |
| 2011 | $-0.30 | 45.47% |
| 2010 | $-0.21 | -75.78% |
| 2009 | $-0.86 | 3.18% |
| 2008 | $-0.84 | 166.41% |
| 2007 | $-0.31 | 191.63% |
| 2006 | $-0.11 | 1,435.71% |
| 2005 | $-0.01 | 75.00% |
| 2004 | 0.00 | 0.00% |
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $17.32 | -1,646.43% |
US
|
|
| $-7.98 | 612.50% |
US
|
|
| $-5.29 | 372.32% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,576.79% |
NL
|
